Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.
View / Open Files
Authors
Au, Lewis
Hatipoglu, Emine
Robert de Massy, Marc
Litchfield, Kevin
Beattie, Gordon
Rowan, Andrew
Schnidrig, Desiree
Thompson, Rachael
Byrne, Fiona
Horswell, Stuart
Fotiadis, Nicos
Hazell, Steve
Nicol, David
Shepherd, Scott TC
Fendler, Annika
Mason, Robert
Del Rosario, Lyra
Edmonds, Kim
Lingard, Karla
Sarker, Sarah
Mangwende, Mary
Carlyle, Eleanor
Attig, Jan
Joshi, Kroopa
Uddin, Imran
Becker, Pablo D
Sunderland, Mariana Werner
Akarca, Ayse
Puccio, Ignazio
Yang, William W
Lund, Tom
Dhillon, Kim
Vasquez, Marcos Duran
Ghorani, Ehsan
Xu, Hang
Spencer, Charlotte
López, José I
Green, Anna
Mahadeva, Ula
Borg, Elaine
Mitchison, Miriam
Moore, David A
Proctor, Ian
Falzon, Mary
Pickering, Lisa
Furness, Andrew JS
Reading, James L
Salgado, Roberto
Marafioti, Teresa
Jamal-Hanjani, Mariam
PEACE Consortium
Kassiotis, George
Chain, Benny
Larkin, James
Swanton, Charles
Quezada, Sergio A
Turajlic, Samra
TRACERx Renal Consortium
Publication Date
2021-11-08Journal Title
Cancer Cell
ISSN
1535-6108
Publisher
Elsevier BV
Volume
39
Issue
11
Pages
1497-1518.e11
Language
eng
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Au, L., Hatipoglu, E., Robert de Massy, M., Litchfield, K., Beattie, G., Rowan, A., Schnidrig, D., et al. (2021). Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.. Cancer Cell, 39 (11), 1497-1518.e11. https://doi.org/10.1016/j.ccell.2021.10.001
Abstract
ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma (ccRCC) aiming to understand the mechanism underpinning therapeutic response. Genomic analyses show no correlation between tumor molecular features and response, whereas ccRCC-specific human endogenous retrovirus expression indirectly correlates with clinical response. T cell receptor (TCR) analysis reveals a significantly higher number of expanded TCR clones pre-treatment in responders suggesting pre-existing immunity. Maintenance of highly similar clusters of TCRs post-treatment predict response, suggesting ongoing antigen engagement and survival of families of T cells likely recognizing the same antigens. In responders, nivolumab-bound CD8+ T cells are expanded and express GZMK/B. Our data suggest nivolumab drives both maintenance and replacement of previously expanded T cell clones, but only maintenance correlates with response. We hypothesize that maintenance and boosting of a pre-existing response is a key element of anti-PD-1 mode of action.
Keywords
T cell receptor, TCR clonal maintenance, TCR clonal replacement, anti-PD-1, autopsy, clear cell renal cell carcinoma, human endogenous retrovirus, multiregion, nivolumab
Identifiers
External DOI: https://doi.org/10.1016/j.ccell.2021.10.001
This record's URL: https://www.repository.cam.ac.uk/handle/1810/330209
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International
Licence URL: https://creativecommons.org/licenses/by-nc-nd/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.